Goodwin Procter advised Avadel Pharmaceutics plc on the deal.Avadel Pharmaceuticals announced an underwritten public offering of 10,000,001 of its ordinary shares, nominal value $0.01 per share…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
